Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.

ABSTRACT:

Background

Patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy sometimes progress at limited sites.The best treatment approach for patients with oligoprogression remains unclear.

Objective

To determine the ability of stereotactic ablative radiation (SAbR) to extend ongoing systemic therapy in mRCC patients with oligoprogression.

Design, setting, and participants

A single-arm phase II clinical trial was conducted at a university medical center and county hospital, including 20 patients with mRCC on first- to fourth-line systemic therapy with three or fewer sites of progression (including new sites) involving ≤30% of all sites.

Intervention

SAbR to oligoprogressing metastases at outset and longitudinally, while radiated sites remain

SUBMITTER: Hannan R 

PROVIDER: S-EPMC9090939 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature